ID,Responder,therapy_start,Abnahmedatum,Baseline,TRIM_PDL1_Expression,therapy_at_blood_draw,ECOG,breslow_thickness_mm,subtype,localization,sex,Alter,Hirnmetastase,adjuvant_IFN,befallen_Organe,Eosinophile,CRP,LDH,S100,BRAF,nras,Stadium
1,,NA,NA,NA,,,,,,,,,,,,,,,,,,
2,,NA,NA,NA,,,,,,,,,,,,,,,,,,
3,ja,Feb 15,31.03.2016,nein,,Pembrolizumab,0,NA,cutanes Melanom,trunk,m,69,,nein,1,4.3,2.3,159,0.04,neg.,,IV
4,nein,Jan 14,31.03.2016,nein,,Dabrafenib/Trametinib,0,8.0 mm,cutanes Melanom,head / neck,m,79,,nein,3,3.3,18.9,231,0.09,pos.,,IV
5,ja,Sep 15,31.03.2016,nein,,Pembrolizumab,0,6.0 mm,cutanes Melanom,acral,m,73,,ja,2,3.1,0.8,290,,neg.,,IV
6,ja,Mrz 15,31.03.2016,nein,,Nivolumab,1,3.0 mm,cutanes Melanom,head / neck,w,82,,nein,3,9.8,5.5,174,0.11,neg.,,IIIC
7,ja,Mrz 14,19.04.2016,nein,,Nivolumab,0,1.65 mm,cutanes Melanom,trunk,m,63,,ja,4,1.1,2.7,239,0.38,neg.,,IV
8,ja,Jan 16,31.03.2016,nein,,Pembrolizumab,0,NA,NA,,m,49,,nein,3,4.6,4.7,233,0.06,pos.,,
9,nein,Mrz 15,31.03.2016,nein,,Nivolumab,0,6.5 mm,cutanes Melanom,extremities,w,44,,ja,2,1.6,0.3,162,,pos.,,IIIC
10,ja,Jan 15,22.04.2016,nein,,Pembrolizumab,0,1.0 mm,cutanes Melanom,extremities,w,63,ja,,2,2,2.3,179,0.05,neg.,pos,IV
11,nein,keine Therapie,29.03.2016,NA,,Ipilimumab,1,9.0 mm,cutanes Melanom,trunk,w,66,,nein,3,0.1,3,256,,neg.,,IV
12,nein,Sep 16,01.04.2016,ja,,Dabrafenib/Trametinib,0,2.25 mm,cutanes Melanom,extremities,m,33,,ja,,0.5,2.1,238,0.08,pos.,,IV
13,nein,Aug 15,01.04.2016,nein,,Pembrolizumab,1,NA,cutanes Melanom,trunk,m,80,,,3,6.5,6.5,252,0.14,neg.,,IV
14,nein,keine Therapie,01.04.2016,NA,,Elektrochemotherapie,1,NA,cutanes Melanom,head / neck,m,69,nein,nein,2,2,5,308,0.23,neg.,,IV
15,nein,Jun 14,01.04.2016,nein,+,Pembrolizumab,0,1.45 mm,cutanes Melanom,,w,44,ja,ja,3,4.9,3.5,204,0.07,pos.,,IV
16,nein,Mrz 16,01.04.2016,ja,,Pembrolizumab,0,5.6 mm,cutanes Melanom,trunk,m,75,,nein,3,1.2,2.4,210,0.77,pos.,,IV
17,NA,keine Therapie,05.04.2016,NA,,Interferon,0,0.95 mm,cutanes Melanom,trunk,w,62,nein,ja,1,1.1,1.6,345,0.06,neg,,IIIC
18,NA,keine Therapie,05.04.2016,NA,++,Placebo i.R. einer Studie,0,1.7 mm,cutanes Melanom,acral,w,52, ,nein,,2.9,0.8,166,0.06,pos.,,IIIB
19,ja,Feb 14,05.04.2016,nein,,MEK-Inhibitor,1,8.0 mm,cutanes Melanom,trunk,w,74,nein,ja,3,2.2,1.2,276,0.11,neg.,,IV
20,nein,Sep 14,07.04.2016,nein,,Pembrolizumab,0,1.5 mm,cutanes Melanom,extremities,w,76,nein,nein,2,2.4,0.6,185,0.04,pos.,,IV
21,NA,keine Therapie,07.04.2016,NA,,-,0,6.48 mm,cutanes Melanom,extremities,m,59,nein,ja,1,0.4,1,190,0.19,pos.,,IIIC
22,ja,Jan 16,07.04.2016,nein,,Pembrolizumab,1,NA,Schleimhautmelanom,head / neck,w,76,ja,,3,0.3,0.2,141,,neg.,,IV
23,ja,Feb 16,07.04.2016,nein,,Pembrolizumab,0,4.2 mm,cutanes Melanom,acral,m,72,nein,nein,1,4.9,0.6,228,0.04,neg.,,IIC/IV
24,nein,Okt 15,07.04.2016,nein,,Pembrolizumab,2,2.8 mm,cutanes Melanom,extremities,m,87,ja,nein,3,3,1.6,207,0.09,pos.,,IV
25,NA,Jun 16,07.04.2016,ja,,Placebo i.R. einer Studie,0,NA,NA,,w,69,nein,nein,3,1.5,2,190,0.15,pos.,,IV
26,nein,Jan 16,12.04.2016,nein,,Pembrolizumab,1,22.0 mm,cutanes Melanom,trunk,m,77,nein,nein,3,0.3,71.3,478,0.56,neg.,,IV
27,nein,Jan 16,12.04.2016,nein,,Pembrolizumab,0,2.9 mm,cutanes Melanom,trunk,w,45,nein,nein,3,1.8,11.6,218,0.02,pos.,,IV
28,nein,Jan 16,12.04.2016,nein,-,Ipilimumab,1,28.0 mm,cutanes Melanom,acral,m,84,nein,nein,1,1.3,285,393,2.42,neg.,,IIIC
29,nein,Mai 16,12.04.2016,ja,,Pembrolizumab,1,0.9 mm,cutanes Melanom,trunk,m,76,nein,nein,3,3,6.6,233,0.06,neg.,,IIIC
30,nein,Apr 17,14.04.2016,ja,,Dabrafenib/Trametinib,0,4.5 mm,cutanes Melanom,extremities,w,60,ja,ja,3,0.2,3.6,233,0.1,pos.,,IV
31,ja,Aug 15,14.04.2016,nein,++,-,0,1.6 mm,cutanes Melanom,extremities,w,73,,,2,4.1,6.5,213,0.08,neg.,,IV
32,ja,Jul 16,30.08.2016,ja,-,-,0,2.0 mm,cutanes Melanom,head / neck,w,, ,,,0.6,13.1,185,0.09,pos.,,IIIC
33,ja,Jun 15,14.04.2016,nein,,Pembrolizumab,0,NA,cutanes Melanom,NA,m,74,nein,nein,1,0.8,3.5,188,0.03,neg.,,IV
34,ja,Okt 13,26.04.2016,nein,,Nivolumab,1,3.2 mm,cutanes Melanom,extremities,w,78,nein,ja,3,1.6,4.6,153,0.09,neg,,IV
35,ja,Apr 16,26.04.2016,ja,,Ipilimumab+Nivolumab,0,8.0 mm,cutanes Melanom,extremities,m,38,nein,nein,3,6.8,4,168,0.05,neg.,,IIIC
36,ja,Jun 15,26.04.2016,nein,,Pembrolizumab,2,NA,NA,NA,m,92,nein,nein,2,2,7.8,185,0.14,neg.,,IV
37,nein,Aug 16,28.04.2016,ja,,Interleukin,0,1.3 mm,cutanes Melanom,head / neck,m,45,nein,ja,1,1.7,5.5,178,0.09,neg.,,IIIC
38,ja,Jul 15,28.04.2016,nein,,Nivolumab,1,5.0 mm,cutanes Melanom,extremities,m,77,ja,nein,2,5,0.4,160,0.07,pos.,,IV
39,nein,Aug 16,28.04.2016,ja,,Encorafenib/Binimetinib,0,12.0 mm,cutanes Melanom,acral,m,36,nein,nein,3,2.3,3.3,203,0.04,pos.,,IV
40,NA,keine Therapie,28.04.2016,NA,,-,0,9.0 mm,cutanes Melanom,head / neck,w,50,nein,ja,1,2,1.2,136,0.1,pos.,,IIIC
41,nein,Mrz 16,03.05.2016,nein,,Pembrolizumab,2,1.4 mm,cutanes Melanom,trunk,m,52,nein,nein,2,2.2,10.2,399,,pos.,,IV
42,NA,keine Therapie,03.05.2016,NA,,-,0,NA,cutanes Melanom,extremities,w,76,,ja,3,1.4,1.3,178,0.07,NA,,IIIC
43,ja,Jun 15,03.05.2016,nein,,Pembrolizumab,1,9.0 mm,Schleimhautmelanom,vulva,w,74,nein,nein,2,3.5,0.6,177,0.1,neg.,,IV
44,ja,Jun 17,10.05.2016,ja,,-,0,NA,Schleimhautmelanom,anal,w,76,nein,nein,0,2.9,0.6,182,0.05,neg.,,
45,NA,Nov 13,10.05.2016,nein,,Dabrafenib/Trametinib,0,23.0 mm,cutanes Melanom,trunk,m,61,nein,,2,0.8,6.3,213,0.05,pos.,,IV
46,nein,Mai 16,12.05.2016,ja,,Ipilimumab+Nivolumab,2,NA,cutanes Melanom,extremities,m,36,nein,nein,1,2.7,1.3,188,0.78,neg.,,IV
47,ja,Feb 16,12.05.2016,nein,,Pembrolizumab,0,4.0 mm,cutanes Melanom,trunk,m,42,ja,ja,2,5.2,10.4,157,0.03,pos.,,IV
48,ja,Feb 14,12.05.2016,nein,,PD-1 bis 05/15 mit Vollremission,0,NA,cutanes Melanom,,m,,,,,1,1.2,195,0.03,pos.,,IV
49,ja,Sep 14,12.05.2016,nein,,Pembrolizumab,1,2.1 mm,cutanes Melanom,head / neck,m,50,ja,ja,2,10,1,166,0.04,pos.,,IV
50,ja,Nov 15,12.05.2016,nein,,Pembrolizumab,1,2.3 mm,cutanes Melanom,trunk,m,85,ja,nein,3,1.5,0.6,192,0.56,neg.,,IV
51,nein,Jul 14,12.05.2016,nein,,Dabrafenib/Trametinib,0,3.2 mm,cutanes Melanom,extremities,w,55,ja,,3,2.4,25.2,290,0.15,pos.,,IV
52,ja,Aug 15,17.05.2016,nein,,Pembrolizumab,0,4.5 mm,cutanes Melanom,trunk,m,72,nein,ja,2,0.6,2,199,0.26,neg.,,IV
53,ja,Feb 15,17.05.2016,nein,++,Nivolumab,0,4.5 mm,cutanes Melanom,trunk,w,36,nein,ja,2,1.2,3.3,128,0.05,neg.,,IV
54,nein,Nov 13,17.05.2016,nein,,Encorafenib,0,0.6 mm,cutanes Melanom,trunk,m,47,nein,,2,3.1,5.4,153,0.02,pos.,,IV
55,NA,keine Therapie,19.05.2016,NA,,-,2,1.1 mm,cutanes Melanom,trunk,m,74,nein,nein,3,1.4,4.6,127,0.03,pos.,,IV
56,NA,keine Therapie,19.05.2016,NA,,Dabrafenib/Trametinib,1,2.25 mm,cutanes Melanom,extremities,w,67,ja,,4,1,12.9,230,0.1,pos.,,IV
57,NA,keine Therapie,19.05.2016,NA,,Ipilimumab 2013 mit complete response,0,4.4 mm,cutanes Melanom,trunk,w,55,nein,ja,2,0,1.5,215,0.06,neg.,,IV
58,ja,Nov 15,19.05.2016,nein,,Pembrolizumab,1,2.25 mm,cutanes Melanom,acral,m,86,nein,nein,1,6.3,3.6,184,0.1,pos.,,IIIC
59,nein,Aug 15,26.05.2016,nein,-,Temozolomid,1,3.0 mm,cutanes Melanom,head / neck,w,79,ja,ja,3,2.9,16.9,237,0.13,neg.,,IV
60,NA,keine Therapie,26.06.2016,NA,,-,1,1.5 mm,cutanes Melanom,head / neck,w,75,,ja,1,12.1,12.8,217,0.08,NA,,IIIC
61,nein,Aug 17,26.05.2016,ja,,-,0,1.3 mm,cutanes Melanom,extremities,w,49,ja,,1,2.7,2.6,146,0.1,pos.,,IV
62,NA,keine Therapie,14.06.2016,NA,,-,0,2.0 mm,cutanes Melanom,acral,w,59,,ja,1,1.4,0.4,189,0.1,NA,,IIIC
63,nein,Jun 16,16.06.2016,ja,,Pembrolizumab,1,5.7 mm,cutanes Melanom,head / neck,m,,,,,1.6,2.5,189,0.08,pos.,,IV
64,NA,keine Therapie,16.06.2016,NA,,-,0,1.7 mm,cutanes Melanom,trunk,m,80,nein,nein,1,5.9,0.3,294,0.06,NA,pos,IIIC
65,nein,keine Therapie,16.06.2016,NA,,Roferon,2,NA,NA,,w,,,,,0.4,0.6,213,0.07,neg.,,IIIC
66,ja,Nov 16,16.06.2016,ja,,-,0,2.5 mm,cutanes Melanom,extremities,m,51,nein,ja,2,12.5,0.5,177,0.04,neg.,,IV
67,nein,Jan 16,16.06.2016,nein,,Pembrolizumab,1,NA,NA,,m,,,,,0.3,15.2,288,0.07,neg.,,IV
68,nein,Aug 16,21.06.2016,ja,,Ipilimumab+Nivolumab,2,8.0 mm,cutanes Melanom,acral,w,,,,,2.4,10.9,200,0.15,pos.,,IV
69,nein,Jun 16,23.06.2016,ja,,Ipilimumab+Nivolumab,1,5.5 mm,cutanes Melanom,trunk,m,67,nein,ja,4,1.1,12.7,228,0.1,neg.,,IV
70,nein,Okt 15,23.06.2016,nein,,Dacarbazin,2,9.0 mm,Schleimhautmelanom,anal,w,,,,,2.1,10.5,333,0.58,neg.,,IV
71,nein,Okt 16,23.06.2016,ja,,Ipilimumab+Nivolumab,1,11.0 mm,cutanes Melanom,trunk,m,83,nein,,4,0.5,1.9,191,0.37,pos.,,IV
72,NA,keine Therapie,05.07.2016,NA,,-,0,0.85 mm,cutanes Melanom,extremities,m,60,nein,nein,1,1.6,1.8,181,0.06,pos.,,IIIC
73,nein,Nov 16,05.07.2016,ja,,-,0,1.4 mm,cutanes Melanom,head / neck,m,81,ja,nein,1,0.2,0.3,310,0.1,neg.,,IV
74,nein,keine Therapie,05.07.2016,NA,,Dabrafenib/Trametinib,0,1.27,cutanes Melanom,trunk,m,39,nein,ja,2,2.9,3.4,241,0.04,pos.,,IV
75,nein,Dez 15,04.08.2016,nein,,Dabrafenib/Trametinib,1,2.7 mm,cutanes Melanom,acral,w,66,ja,nein,3,1.3,4.6,211,0.12,pos.,,IV
76,NA,Jan 17,04.08.2016,ja,++,-,0,4.2 mm,cutanes Melanom,extremities,m,,,,,8.8,1.2,201,0.03,neg.,,IV
77,NA,keine Therapie,04.08.2016,NA,,Interferon alpha,0,2.0 mm,cutanes Melanom,extremities,m,43,nein,ja,1,1.6,0.9,189,0.02,pos.,,IIIA
78,nein,Jul 16,11.08.2016,nein,,Ipilimumab+Nivolumab,1,1.1 mm,cutanes Melanom,trunk,w,,,,,7.3,1.2,250,0.57,NA,pos,IV
79,ja,Aug 14,11.08.2016,nein,,Bis 02/16 Pembro mit complete response,1,1.0 mm,cutanes Melanom,trunk,w,75,nein,nein,3,0.4,7.7,214,0.07,pos.,,IV
80,nein,Sep 15,18.08.2016,nein,++,Dabrafenib/Trametinib,0,3.61 mm,cutanes Melanom,head / neck,w,31,ja,ja,2,2.3,4.5,188,0.06,pos.,,IV
81,ja,Dez 15,23.08.2016,nein,,Pembrolizumab,0,1.95 mm,cutanes Melanom,extremities,w,57,ja,nein,2,5.9,0.6,169,0.04,pos.,,IV
82,nein,Okt 13,25.08.2016,nein,,Ipilimumab+Nivolumab,1,NA,Schleimhautmelanom,anal,w,,,,,4.3,47.2,2022,2.07,NA,pos,IV
83,nein,Mai 16,30.08.2016,nein,,Nivolumab,1,0.78 mm,cutanes Melanom,extremities,m,,,,,0.2,21.6,235,5.41,pos.,,IV
84,NA,keine Therapie,30.08.2016,NA,,Dabrafenib/Trametinib,0,1.27 mm,cutanes Melanom,trunk,m,38,nein,nein,3,3,3.8,210,0.07,pos.,,IV
85,ja,Nov 16,30.08.2016,ja,,-,0,2.5 mm,cutanes Melanom,extremities,w,52,nein,ja,4,12.4,0.5,177,0.05,neg.,,IV
86,nein,Sep 16,15.09.2016,ja,,Pembrolizumab,0,14.0 mm,cutanes Melanom,trunk,w,49,nein,ja,1,4.1,8.8,195,0.3,pos.,,IV
87,NA,keine Therapie,27.10.2016,NA,,Dabrafenib/Trametinib,1,3.2 mm,cutanes Melanom,trunk,m,71,nein,,1,4.9,4.7,385,0.23,pos.,,IV
88,nein,Mai 16,27.10.2017,nein,,Vemurafenib + Cobimetinib,0,0.95 mm,cutanes Melanom,trunk,w,63,nein,nein,1,1.1,29.7,409,0.13,pos.,,IIIc
89,NA,keine Therapie,03.11.2016,NA,,-,0,2.1 mm,cutanes Melanom,head / neck,w,73,nein,nein,3,5.1,5.2,195,0.08,neg,,IV
90,ja,Dez 16,10.11.2016,ja,,-,0,9.2 mm,cutanes Melanom,trunk,m,76,,nein,1,5.4,1.7,183,0.94,pos.,,iV
91,nein,Nov 16,22.11.2016,ja,,Nivolumab,2,38.0 mm,cutanes Melanom,trunk,m,,,,,0.3,110.6,414,,neg.,,IV
92,ja,Nov 16,22.11.2016,ja,,Pembrolizumab,0,5.6 mm,cutanes Melanom,head / neck,m,69,nein,nein,1,3.1,1.6,235,0.07,neg,,iV
93,ja,Jun 16,24.11.2016,nein,,Nivolumab,0,1.0 mm,cutanes Melanom,trunk,m,,,,,0,1.3,194,0.05,pos.,,IV
94,nein,Mai 16,24.11.2016,nein,,-,2,NA,cutanes Melanom,extremities,m,,,,,0.6,10.2,234,1.14,neg.,,IV
95,ja,Nov 16,24.11.2016,ja,,Pembrolizumab,0,8.0 mm,cutanes Melanom,acral,m,76,nein,nein,2,2.6,6.1,173,0.24,neg.,,IV
96,nein,Sep 17,29.11.2016,ja,,Ipilimumab+Nivolumab,1,NA,NA,NA,w,45,,nein,1,0.4,0.2,305,0.1,pos.,,IV
97,nein,Nov 16,01.12.2016,ja,,Dabrafenib/Trametinib,1,NA,cutanes Melanom,trunk,w,,,,,6,2.4,161,0.23,pos.,,IV
98,NA,Okt 17,01.12.2016,ja,,-,0,3.2 mm,cutanes Melanom,trunk,m,73,nein,nein,1,1.8,1.5,216,0.02,neg.,,Iib
99,ja,Dez 16,07.12.2016,ja,,Pembrolizumab,1,7.0 mm,cutanes Melanom,trunk,m,78,nein,nein,3,2.7,6.6,296,0.1,pos.,,IV
100,nein,Dez 16,07.12.2016,ja,,Ipilimumab+Nivolumab,1,0.7 mm,cutanes Melanom,trunk,m,52,,nein,1,0,0.5,277,1.09,neg.,,IV
101,ja,Jan 17,10.01.2017,ja,,Ipilimumab+Nivolumab,0,3.25 mm,cutanes Melanom,head / neck,m,,,,,3.1,2.3,194,0.07,pos.,,
102,nein,Jan 17,17.01.2017,ja,,Ipilimumab+Nivolumab,0,1.7 mm,cutanes Melanom,head / neck,m,51,ja,nein,4,2.6,80.8,569,3.64,pos.,,IV
103,ja,Okt 16,17.01.2017,nein,o,Pembrolizumab,2,3.2 mm,cutanes Melanom,acral,m,,nein,nein,2,0.4,11,248,0.1,neg.,,IV
